Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: An effective in vitro drug-sensitization system

Ayinan Al-Hendy, Nelly Auersperg

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Ovarian cancer is a major clinical problem with no rewarding treatment protocol currently available. In other malignancies transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells using a viral vector followed by administration of ganciclovir (GCV) provides a potentially effective strategy for treatment. In this work human ovarian epithelial cancer cell lines were infected with a recombinant adenoviral vector expressing the HSV-tk (AdRSV-tk) and were rendered sensitive to doses of GCV that were 100-200 times less than for untransfected cells. A strong bystander effect was noted with significant killing at a ratio of infected:uninfected cells of only 1:20 and maximal killing at 1:3. Normal human ovarian surface epithelial cells were also highly sensitive to the AdRSV-tk/GCV system. This study demonstrates the potential efficacy of the HSV-tk/GCV approach in ovarian cancer gene therapy.

Original languageEnglish (US)
Pages (from-to)268-275
Number of pages8
JournalGynecologic and Obstetric Investigation
Volume43
Issue number4
DOIs
StatePublished - Jan 1 1997

Fingerprint

Ganciclovir
Thymidine Kinase
Simplexvirus
Ovarian Neoplasms
Pharmaceutical Preparations
Epithelial Cells
Bystander Effect
Neoplasm Genes
Clinical Protocols
Genetic Therapy
Neoplasms
Cell Line
In Vitro Techniques
Genes
Therapeutics

Keywords

  • Adenovirus
  • Ganciclovir
  • Gene therapy
  • Ovarian cancer
  • Thymidine kinase

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer : An effective in vitro drug-sensitization system. / Al-Hendy, Ayinan; Auersperg, Nelly.

In: Gynecologic and Obstetric Investigation, Vol. 43, No. 4, 01.01.1997, p. 268-275.

Research output: Contribution to journalArticle

@article{d80c33bcadcc480384e67eb94c66b889,
title = "Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: An effective in vitro drug-sensitization system",
abstract = "Ovarian cancer is a major clinical problem with no rewarding treatment protocol currently available. In other malignancies transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells using a viral vector followed by administration of ganciclovir (GCV) provides a potentially effective strategy for treatment. In this work human ovarian epithelial cancer cell lines were infected with a recombinant adenoviral vector expressing the HSV-tk (AdRSV-tk) and were rendered sensitive to doses of GCV that were 100-200 times less than for untransfected cells. A strong bystander effect was noted with significant killing at a ratio of infected:uninfected cells of only 1:20 and maximal killing at 1:3. Normal human ovarian surface epithelial cells were also highly sensitive to the AdRSV-tk/GCV system. This study demonstrates the potential efficacy of the HSV-tk/GCV approach in ovarian cancer gene therapy.",
keywords = "Adenovirus, Ganciclovir, Gene therapy, Ovarian cancer, Thymidine kinase",
author = "Ayinan Al-Hendy and Nelly Auersperg",
year = "1997",
month = "1",
day = "1",
doi = "10.1159/000291870",
language = "English (US)",
volume = "43",
pages = "268--275",
journal = "Gynecologic and Obstetric Investigation",
issn = "0378-7346",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer

T2 - An effective in vitro drug-sensitization system

AU - Al-Hendy, Ayinan

AU - Auersperg, Nelly

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Ovarian cancer is a major clinical problem with no rewarding treatment protocol currently available. In other malignancies transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells using a viral vector followed by administration of ganciclovir (GCV) provides a potentially effective strategy for treatment. In this work human ovarian epithelial cancer cell lines were infected with a recombinant adenoviral vector expressing the HSV-tk (AdRSV-tk) and were rendered sensitive to doses of GCV that were 100-200 times less than for untransfected cells. A strong bystander effect was noted with significant killing at a ratio of infected:uninfected cells of only 1:20 and maximal killing at 1:3. Normal human ovarian surface epithelial cells were also highly sensitive to the AdRSV-tk/GCV system. This study demonstrates the potential efficacy of the HSV-tk/GCV approach in ovarian cancer gene therapy.

AB - Ovarian cancer is a major clinical problem with no rewarding treatment protocol currently available. In other malignancies transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells using a viral vector followed by administration of ganciclovir (GCV) provides a potentially effective strategy for treatment. In this work human ovarian epithelial cancer cell lines were infected with a recombinant adenoviral vector expressing the HSV-tk (AdRSV-tk) and were rendered sensitive to doses of GCV that were 100-200 times less than for untransfected cells. A strong bystander effect was noted with significant killing at a ratio of infected:uninfected cells of only 1:20 and maximal killing at 1:3. Normal human ovarian surface epithelial cells were also highly sensitive to the AdRSV-tk/GCV system. This study demonstrates the potential efficacy of the HSV-tk/GCV approach in ovarian cancer gene therapy.

KW - Adenovirus

KW - Ganciclovir

KW - Gene therapy

KW - Ovarian cancer

KW - Thymidine kinase

UR - http://www.scopus.com/inward/record.url?scp=0031010299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031010299&partnerID=8YFLogxK

U2 - 10.1159/000291870

DO - 10.1159/000291870

M3 - Article

C2 - 9194627

AN - SCOPUS:0031010299

VL - 43

SP - 268

EP - 275

JO - Gynecologic and Obstetric Investigation

JF - Gynecologic and Obstetric Investigation

SN - 0378-7346

IS - 4

ER -